Literature DB >> 9366308

Urodynamic effects of various treatment modalities for benign prostatic hyperplasia.

J L Bosch1.   

Abstract

PURPOSE: I studied the effects of various treatments for benign prostatic hyperplasia on urethral resistance.
MATERIALS AND METHODS: I reviewed the literature on urodynamic effects of treatments for benign prostatic hyperplasia. Articles that reported pretreatment and posttreatment values of relevant urodynamic parameters were analyzed. Average before and after treatment values of maximum flow rate and detrusor pressure at maximal flow rate for every study were plotted on an Abrams-Griffiths nomogram and classified as obstructed, equivocal or nonobstructed. Average values of maximum flow rate and detrusor pressure at maximal flow rate were calculated for the total number of patients treated by a certain modality.
RESULTS: Based on this analysis, the rank order of urodynamic efficacy was that open prostatectomy is more effective in reducing urethral resistance than is transurethral prostatectomy. These treatments diminish obstruction better than laser treatment or transurethral incision of the prostate, which again are more effective than balloon dilation, alpha-blockers or transurethral microwave thermotherapy. Finally, androgen deprivation performs better than placebo treatment.
CONCLUSIONS: The rank order of urodynamic efficacy as determined in this analysis shows a high level of agreement with reported rank order of symptomatic efficacy of various modalities. After placebo treatment there is no significant change in urethral resistance. This finding indicates that pressure-flow studies are a sensitive way to compare active to placebo treatment and that pressure-flow studies have excellent long-term reproducibility.

Entities:  

Mesh:

Year:  1997        PMID: 9366308     DOI: 10.1016/s0022-5347(01)68149-7

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  5 in total

1.  [S2e guideline of the German urologists: Conservative and pharmacologic treatment of benign prostatic hyperplasia].

Authors:  K Höfner; T Bach; R Berges; K Dreikorn; C Gratzke; S Madersbacher; M-S Michel; R Muschter; M Oelke; O Reich; C Tschuschke; T Bschleipfer
Journal:  Urologe A       Date:  2016-02       Impact factor: 0.639

2.  Efficacy of alpha-Adrenergic Receptor Blockers in the Treatment of Male Lower Urinary Tract Symptoms.

Authors:  Claus G Roehrborn
Journal:  Rev Urol       Date:  2009

Review 3.  Changing therapeutic regimens in benign prostatic hyperplasia. Clinical and economic considerations.

Authors:  H J Stoevelaar; J McDonnell
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 4.  The role of urodynamics in the diagnosis and treatment of benign prostatic hyperplasia.

Authors:  J Quentin Clemens
Journal:  Curr Urol Rep       Date:  2003-08       Impact factor: 2.862

Review 5.  Do functional changes occur in the bladder due to bladder outlet obstruction? - ICI-RS 2018.

Authors:  Ruud Bosch; Paul Abrams; Marcio Augusto Averbeck; Enrico Finazzi Agró; Andrew Gammie; Tom Marcelissen; Eskinder Solomon
Journal:  Neurourol Urodyn       Date:  2019-07-06       Impact factor: 2.696

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.